

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/131835/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Choy, Ernest H. , De Benedetti, Fabrizio, Takeuchi, Tsutomu, Hashizume, Misato, John, Markus R. and Kishimoto, Tadimitsu 2020. Translating IL-6 biology into effective treatments. *Nature Reviews Rheumatology* 16 , pp. 335-345.
10.1038/s41584-020-0419-z

Publishers page: <http://dx.doi.org/10.1038/s41584-020-0419-z>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



1 **Translating IL-6 biology into effective treatments**

2 Ernest H. Choy,^{1†} Fabrizio De Benedetti,² Tsutomu Takeuchi,³ Misato Hashizume,⁴ Markus
3 R. John,⁵ and Tadimitsu Kishimoto⁶

4
5
6 ¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, UK.

7 ²Division of Rheumatology and Laboratory of ImmunoRheumatology, Ospedale Pediatrico
8 Bambino Gesù, Roma Italy.

9 ³Division of Rheumatology, Department of Internal Medicine, Keio University School of
10 Medicine, Tokyo, Japan.

11 ⁴Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

12 ⁵F. Hoffmann-La Roche AG, Basel, Switzerland

13 ⁶Laboratory of Immune Regulation, World Premier International Immunology Frontier
14 Research Center, Osaka University, Osaka, Japan.

15
16 †email: ChoyEH@Cardiff.ac.uk

17
18
19 **ABSTRACT**

20 In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for
21 antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway
22 has emerged as a pivotal pathway involved in immune regulation in health and dysregulation
23 in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches

24 for various rheumatic conditions such as rheumatoid arthritis, juvenile idiopathic arthritis,
25 adult onset Still's disease, giant cell arteritis, Takayasu arteritis, and others such as
26 Castleman's disease or cytokine release syndrome. Targeting this pathway [Au:OK?Yes] has
27 also identified avenues for potential expansion into several other indications, such as uveitis
28 and neuromyelitis optica. To mark the tenth anniversary of anti-IL-6-receptor therapy
29 worldwide, we discuss the history of research into IL-6 biology and the development of
30 therapies that target IL-6 signalling, including the successes and challenges and with an
31 emphasis on rheumatic diseases.

32

33

34 [H1] Introduction

35

36 Cytokine inhibitors have transformed the outcome of many chronic inflammatory diseases. A
37 decade has passed since the approval of anti-IL-6-receptor (anti-IL-6R) therapy, which is
38 now used worldwide in various rheumatic conditions such as rheumatoid arthritis (RA),
39 juvenile idiopathic arthritis (JIA), adult onset Still's disease (AOSD), giant cell arteritis
40 (GCA) and Takayasu arteritis, as well as other conditions such as Castleman's disease and
41 cytokine release syndrome (CRS). To mark this anniversary, we discuss the 40-year history
42 of translational research into IL-6 biology and the subsequent development of therapies
43 targeting this pivotal cytokine pathway, which helps to inform future biologic and clinical
44 research. [Au: Edits have been made to clarify this introductory text, to break up a very
45 long sentence and to avoid repeating wording used in the abstract – edited text
46 OK?Yes]

47

48 [H1] From signalling to drug discovery

49 The journey from the discovery of IL-6 biology to the development of an IL-6 pathway
50 inhibitor as a potential treatment for various diseases started coincidentally with the meeting
51 of two research groups in Japan. In 1973, researchers at Osaka University led by Tadamitsu
52 Kishimoto first reported that a soluble factor secreted by T cells was important for antibody
53 production by B cells (Figure 1); subsequently, this soluble factor was cloned as IL-6, which
54 turned out to have various roles in several autoimmune diseases.^{1,2} At the same time,
55 researchers at Chugai Pharmaceutical were exploring new avenues for drug development for
56 autoimmune diseases. In the late 1980s, the two groups started to collaborate to further

Commented [A1]: Original text, FYI:
“To mark the tenth anniversary of approved anti-IL-6-receptor therapy worldwide, we discuss the 40 year history of translational research into IL-6 biology and the subsequent development of therapies targeting this pivotal cytokine pathway which include various rheumatic conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, adult onset Still's disease, giant cell arteritis, Takayasu arteritis, and others such as Castleman's disease or cytokine release syndrome that helps to inform future biologic and clinical research.”

57 advance the understanding of the biological role of IL-6 in various autoimmune diseases and
58 the development of IL-6 inhibitors as treatment options. To increase their collaborative
59 potential, the two research groups even moved to adjoined laboratories at Osaka University.
60 The university researchers led efforts to identify IL-6 signalling mechanisms and the biologic
61 effects of IL-6, whereas the company focused on developing and characterizing IL-6
62 inhibitors as potential new treatments for autoimmune diseases.³⁻⁵

63 The traditional approach of searching for small-molecule inhibitors proved challenging when
64 the research team found that IL-6 signal transduction occurred through a hexameric high-
65 affinity complex of IL-6, IL-6R and glycoprotein 130 (gp130) (Figure 2). Moreover, both
66 soluble IL-6R (sIL-6R) and membrane-bound IL-6R (mIL-6R) can be part of the hexameric
67 complex; hence, the binding region of IL-6–IL-6R–gp130 was considered too complex and
68 broad for a small molecule compound to inhibit the IL-6 signal pathway.^{6,7} The
69 aforementioned mIL-6R and sIL-6R forms are associated with so-called classical and trans
70 signalling pathways, respectively, the details of which and corresponding avenues for drug
71 development have been reviewed extensively elsewhere.⁴ Both signalling routes involve
72 phosphorylation of Janus kinase 1 (JAK1), JAK2 and tyrosine kinase 2 (TYK2), which can
73 also be targeted therapeutically with different molecules but are not the focus of this article.⁴

74 The decision to target sIL-6R rather than IL-6 itself was made taking into consideration that
75 concentrations of the receptor have less interpatient variability than concentrations of IL-6,
76 potentially simplifying dose and regimen selection.^{8,9} With concurrent advances in
77 biotechnology, the two groups decided to develop a humanized monoclonal antibody
78 targeting IL-6R.¹⁰⁻¹² The resulting humanized anti-IL-6R antibody, tocilizumab, binds to
79 mIL-6R and sIL-6R and inhibits IL-6 signalling by preventing IL-6 from binding to IL-6R.¹¹
80 ¹² The therapeutic benefit of this anti-IL6R antibody led to the development of several anti-
81 IL-6 antibodies (sirukumab, olokizumab and clazakizumab).

82

83 **[H1] Initial therapeutic applications**

84 As IL-6 is well known to have various physiological roles, in considering IL-6 as a
85 therapeutic target its homeostatic role versus its pathogenic role in various autoimmune
86 diseases was extensively debated.^{3,4} However, utilizing cell-based assays, animal models
87 and ex vivo serum and tissue analyses, scientists identified several candidate diseases that
88 might benefit from the use of IL-6 inhibition (Table 1).

89 A 1988 publication reported that IL-6 is an important growth factor in myeloma cells.¹³
90 Oncologists in France conducted an open-label clinical trial of a mouse anti-IL-6 antibody in
91 patients with multiple myeloma, the second most common type of blood cancer after
92 leukemia.¹⁴ Although none of the patients treated had an improved outcome or achieved
93 remission in the initial report of the trial, post hoc analysis revealed that treatment with the
94 anti-IL-6 antibody showed some efficacy in those patients who produced low concentrations
95 of IL-6.¹⁵ More than 20 years later, a clinical trial evaluated whether the addition of a
96 different chimeric anti-IL-6 monoclonal antibody, siltuximab, to the bortezomib–melphalan–
97 prednisone regimen would be beneficial to patients with newly diagnosed multiple myeloma;
98 however, this IL-6 inhibitor also failed to improve outcomes.¹⁶

99 In 1989, a publication described constitutive overproduction of IL-6 from the germinal
100 centers of hyperplastic lymph nodes in patients with Castleman's disease, a
101 lymphoproliferative disorder, and a correlation of serum IL-6 concentrations with clinical
102 abnormalities.¹⁷ Consistent with these observations, transgenic mice carrying the human *IL6*
103 gene, under the control of an immunoglobulin promoter, developed clinical features of
104 Castleman's disease including splenomegaly, lymph node enlargement, and high
105 concentrations of IL-6 and IgG.^{18,19} In a 1994 case report, administration of a mouse anti-IL-

106 6 neutralizing antibody to a patient with Castleman's disease seemed to be therapeutically
107 effective.²⁰ Tocilizumab also had positive effects in a small case series of seven patients in
108 2000 and in a multicentre prospective open-label study in 2005 that included 28 patients with
109 Castleman's disease.^{21,22} In the prospective study [Au:OK? Yes], bi-weekly treatment with
110 tocilizumab consistently alleviated lymphadenopathy and improved all inflammatory
111 parameters over 60 weeks.²² A double-blind placebo-controlled trial of siltuximab also
112 showed efficacy in this indication.²³ Subsequently, tocilizumab was approved for the
113 treatment of Castleman's disease in Japan and siltuximab was approved for this indication in
114 various countries.

115 A 1995 study reported that serum concentrations of IL-6 and sIL-6R were elevated in patients
116 with Crohn's disease, a type of inflammatory bowel disease, and correlated with C-reactive
117 protein levels.²⁴ On the basis of these observations, tocilizumab was evaluated in a phase II
118 randomized placebo-controlled trial (RCT) with patients with active Crohn's disease (defined
119 as Crohn's Disease Activity Index [CDAI] score ≥ 150).²⁵ The primary end point, a reduction
120 of CDAI ≥ 70 points, was met by 80% of the patients who received bi-weekly tocilizumab,
121 compared with 31% of the placebo-treated patients, demonstrating the substantial efficacy of
122 tocilizumab. However, the development of tocilizumab for Crohn's disease did not proceed
123 owing to rare reports of gastrointestinal perforations observed in concurrent clinical trials in
124 arthritis and because of an increased understanding of the homeostatic role of IL-6 in the
125 intestinal epithelium.²⁶ Together, these findings suggested that patients with Crohn's disease
126 might be at increased risk of potential detrimental effects of IL-6 inhibition.

127

128 **[H1] IL-6 inhibition in RA**

129 The development path for an IL-6 inhibitor for the treatment of rheumatoid arthritis (RA), the
130 most common chronic autoimmune disorder that primarily affects joints, began in the early
131 1990s, when cell-based experiments revealed that IL-6 might be involved in osteoporosis,
132 cartilage destruction and synovial inflammation associated with RA.^{27-29,30} In mouse models
133 of collagen-induced and antigen-induced arthritis, IL-6 inhibition prevented the development
134 of arthritis but did not ameliorate arthritis once the disease was established.³¹⁻³³ In a 1993
135 study, the administration of a mouse anti-IL-6 monoclonal antibody to patients with RA
136 resulted in improvements of disease symptoms and laboratory measures of disease activity,
137 although the effects were transient.³⁴ In 2000, the efficacy and tolerability of tocilizumab was
138 investigated in a case series of 11 patients with refractory RA; the treatment was well
139 tolerated and led to both clinical and biochemical improvements.³⁵ On the basis of these
140 results, larger and confirmatory double-blind RCTs of tocilizumab were conducted in patients
141 with refractory RA.³⁶⁻⁴⁰ Tocilizumab improved clinical signs and symptoms of RA,
142 laboratory parameters and radiological manifestations, and also ameliorated the effects of RA
143 on patient reported outcomes, activities of daily living and quality of life, when administered
144 as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs).⁴¹⁻⁴⁵
145 These and other studies led to tocilizumab receiving marketing authorization (Figure 1) for
146 patients with early RA not previously treated with methotrexate and those with established
147 RA and an inadequate response to previous treatment with DMARDs or TNF antagonists; in
148 these patients, tocilizumab is administered in combination with methotrexate or as
149 monotherapy if methotrexate is not tolerated or continued treatment with methotrexate is not
150 appropriate.

151 A notable finding of further clinical investigation in several RCTs and real-world data was
152 that, unlike TNF inhibitors, tocilizumab monotherapy was superior to methotrexate or other
153 csDMARDs for reducing the signs, symptoms and radiographic progression of RA.^{39, 40, 46-59}

154 In particular, a head-to-head, double-blind, double-dummy RCT found that, when used as
155 monotherapy, tocilizumab was superior to the TNF inhibitor adalimumab in measures of
156 disease activity and several other outcomes.⁴⁶ On the basis of these results, EULAR
157 recommendations for the management of RA named IL-6 pathway inhibitors as one of the
158 preferred treatment options for patients for whom methotrexate is inappropriate.⁶⁰
159 Interestingly, the clinical benefits of IL-6 inhibition might be attributable, in part, to the
160 beneficial effects of IL-6 inhibition on bone and cartilage turnover, which are supported by
161 data from prospective cohort studies showing that tocilizumab monotherapy achieves better
162 repair of focal bone erosions than TNF inhibition in patients with RA.⁶⁰⁻⁷⁰ Besides promoting
163 joint inflammation and damage through effects on chondrocytes, osteoclasts, macrophages
164 and fibroblasts, IL-6 mediates systemic inflammation in RA. IL-6 affects T and B cell
165 differentiation, and is the key driver of the acute phase response in RA. Key symptoms and
166 comorbidities such as pain, fatigue, anxiety, depression, anaemia and cardiovascular disease
167 can be mediated by IL-6 [refs ^{71,72}], as shown in Figure 3.

168 Since tocilizumab was approved for RA, sarilumab, an alternative anti-IL-6R monoclonal
169 antibody, has also demonstrated efficacy and safety and has been approved for the treatment
170 of RA.⁷³⁻⁷⁵ Three other anti-IL-6 monoclonal antibodies, sirukumab, olokizumab and
171 clazakizumab, have also been tested in clinical trials in RA. In phase III RCTs that included
172 patients with RA refractory to treatment with csDMARD and biologic DMARDs, sirukumab
173 was superior to placebo in improving disease activity, physical function and health related
174 quality of life, as well as inhibiting radiographic disease progression.^{76,77} However,
175 monotherapy with sirukumab was similar but not superior to adalimumab and efforts to
176 obtain regulatory approval in RA were terminated.⁷⁸ Phase II trials of olokizumab
177 demonstrated therapeutic benefit and phase III trials are ongoing.⁷⁹ However, the
178 development of clazakizumab as a treatment for RA has also been terminated.

179

180 **[H1] IL-6 inhibition in JIA and AOSD**

181 JIA is a term encompassing all forms of chronic arthritis affecting children younger than 16
182 years of age.⁸⁰ JIA exists as several different subtypes: oligoarticular JIA, polyarticular JIA,
183 juvenile psoriatic arthritis, enthesitis-related arthritis and systemic JIA (sJIA). In sJIA,
184 arthritis is associated with prominent systemic features, including high spiking fever, rash,
185 serositis, and inflammatory signs. This disease is further characterized by high morbidity and
186 mortality rates, joint destruction, functional disability, and growth retardation.⁸⁰
187 Concentrations of IL-6 are markedly elevated in the serum and synovial fluid of patients with
188 sJIA and a vast body of evidence from cell-based experiments and animal models
189 demonstrates that IL-6 overproduction seems to explain most, if not all, of the clinical and
190 laboratory features of the disease including fever spikes, acute phase response, anaemia,
191 growth retardation and systemic osteoporosis.⁸¹⁻⁸⁵ In 2005, clinical trials of tocilizumab in
192 patients with sJIA conducted in the UK and Japan provided proof of principle of the efficacy
193 of IL-6 inhibition in this severe pediatric condition.^{86, 87} Two subsequent trials of tocilizumab
194 in >150 children with sJIA confirmed extensive improvements in the signs and symptoms of
195 disease following treatment with tocilizumab and demonstrated clinically relevant
196 glucocorticoid-sparing potential of IL-6 inhibition.⁸⁸⁻⁹² The efficacy and safety of IL-6
197 inhibition in sJIA has also been confirmed in real-world studies.⁹³ Reversal of sJIA-
198 associated growth retardation has also been demonstrated with IL-6 inhibition, with patients
199 experiencing catch-up growth during treatment with tocilizumab.⁹²

200 AOSD and sJIA are increasingly considered to be the same disease, with AOSD occurring in
201 adulthood and sJIA in childhood. In a double-blind RCT of 27 patients with AOSD refractory
202 to treatment with glucocorticoids, an ACR50 response (reflecting 50% improvement) at week

203 4 was achieved in ~61% of patients treated with tocilizumab, compared with ~31% of
204 placebo-treated patients, although the difference was not statistically significant.⁹⁴ Patients in
205 the tocilizumab group also had improvements in systemic symptoms and a decreased dose of
206 glucocorticoids compared with the placebo group. On the basis of data from this trial,
207 tocilizumab was approved for the treatment of AOSD in Japan in 2019.

208 Polyarticular JIA is characterized by a potentially destructive disease course. Trials of
209 tocilizumab were undertaken in polyarticular JIA from 2009 on the basis of results obtained
210 in RA. In a small trial in 19 patients, 100% of patients met the criteria for a good response
211 after 48 weeks of treatment with tocilizumab.⁹⁵ In a pivotal phase III trial and its subsequent
212 long-term extension study in 188 patients, inhibition of IL-6 led to sustained and clinically
213 meaningful improvements after 2 years and skeletal growth was also improved by treatment
214 with tocilizumab.^{96,97} Another anti-IL-6R antibody, sarilumab, is in phase II trials for
215 polyarticular JIA.⁹⁸ and sJIA⁹⁹.

216

217 **[H1] IL-6 inhibition in SpA**

218 Seronegative spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases includin
219 ankylosing spondylitis (AS) and psoriatic arthritis (PsA) with common clinical and
220 aetiological features such as axial and peripheral inflammatory arthritis, enthesitis and extra-
221 articular manifestations.¹⁰⁰ The absence of the serological markers rheumatoid factor (RF)
222 and antibodies against cyclic citrullinated peptides differentiate SpA from RA. AS is a
223 chronic, debilitating and gradually progressive inflammatory rheumatic disease that primarily
224 affects the axial skeleton and sacroiliac joints but can also affect the peripheral joints.¹⁰¹
225 Serum IL-6 concentrations are elevated in patients with AS and correlate with disease
226 activity.¹⁰² However, tocilizumab failed to show therapeutic benefit in AS in two double-

227 blind RCTs in 2014.¹⁰³ Sarilumab was also ineffective as a treatment for AS in a 2015 RCT.

228 ¹⁰⁴ The conclusion from these RCTs is that IL-6 is not a therapeutic target in AS.

229 PsA is a chronic immune-mediated disease characterized by widespread musculoskeletal
230 inflammation and is the major comorbidity associated with psoriasis.¹⁰⁵ The rationale for
231 inhibiting IL-6 in PsA was based on a small number of studies that demonstrated elevated
232 concentrations of IL-6 in both the serum and synovial fluid of patients with PsA.^{106, 107} In a
233 placebo-controlled phase II RCT, clazakizumab improved arthritis, enthesitis and dactylitis in
234 patients with PsA but with minimal improvements in skin disease.¹⁰⁸ Currently, development
235 of clazakizumab for this indication seems to have been terminated.

236

237 **[H1] IL-6 inhibition in SLE and SSc**

238 In 1990, a study in NZB/W F1 mice, an animal model of systemic lupus erythematosus
239 (SLE), suggested that IL-6 could have a role in the pathogenesis of immune complex-
240 mediated glomerulonephritis.¹⁰⁹ Moreover, IL-6 concentrations are elevated in serum and
241 urine samples from patients with SLE or lupus nephritis, and correlate with disease activity.

242 ^{110, 111} In an open-label phase I study in 16 patients with SLE, treatment with tocilizumab
243 improved disease activity; notably, arthritis improved in all seven patients who had arthritis at
244 baseline and resolved in four of them.^{112, 113} Levels of anti-double-stranded DNA antibodies
245 decreased even after adjustment for the decrease in total IgG titres following tocilizumab
246 treatment.¹¹² These changes, together with a decrease in the frequency of circulating plasma
247 cells, suggested a specific effect of IL-6 inhibition on autoantibody-producing B cells.

248 However, further studies with sirukumab did not demonstrate a clinically meaningful benefit
249 of IL-6 pathway inhibition in patients with lupus nephritis or SLE.^{114, 115} These conflicting

250 results in SLE have tempered further clinical development. Whether IL-6 inhibition might be
251 effective for some manifestations of SLE and not others requires further studies.

252 IL-6 is also implicated in the pathogenesis of systemic sclerosis (SSc). In the bleomycin
253 mouse model of SSc, IL-6 blockade reduced skin fibrosis, α smooth-muscle actin protein
254 expression, hydroxyproline content, and myofibroblast counts.¹¹⁶ Dermal fibroblasts from
255 patients with SSc constitutively express more IL-6 than those from healthy controls, and
256 serum IL-6 concentrations are elevated in patients with early SSc.^{117, 118} In a 2010 report,
257 softening of skin sclerosis was observed in two patients with diffuse cutaneous SSc who
258 received tocilizumab treatment.¹¹⁹ In a double-blind phase II RCT in 87 patients with active
259 diffuse SSc, fewer patients in the tocilizumab group had a decline in forced vital capacity
260 compared with the placebo group, but improvements in skin thickening (measured by
261 modified Rodnan skin score) with tocilizumab were not statistically significant.¹²⁰ Results of
262 a follow-up phase III double-blind, placebo-controlled trial in 212 patients with progressive
263 SSc again showed a numerical reduction in skin score with tocilizumab at week 48 but the
264 difference did not reach statistical significance.¹²¹ Regarding the mean change in forced vital
265 capacity from baseline to week 48, tocilizumab performed better than placebo, suggesting a
266 potentially clinically important effect of tocilizumab on preservation of lung function.¹²¹
267 Studies with larger sample size will better define clinical benefit and identify specific SSc
268 patient population for IL-6 inhibition.

269

270 **[H1] IL-6 inhibition in vasculitis and PMR**

271 Takayasu arteritis and GCA are chronic, potentially life-threatening, primary systemic large-
272 vessel vasculitides^{122, 123}. Takayasu arteritis affects the aorta and its major branches in

273 adolescents and young adults, whereas GCA affects large and medium-sized arteries and
274 usually affects individuals above the age of 50 years.

275 IL-6 has been implicated as an important factor in the pathogenesis of both GCA and
276 Takayasu arteritis in the 1990s. First, serum level of IL-6 correlated with disease activity in
277 both diseases.^{124, 125} Second, tocilizumab improved disease signs and symptoms in patients
278 with refractory GCA or refractory Takayasu arteritis in case series. Subsequently, a single-
279 centre phase II RCT and a phase III multicenter, double-blind RCT investigated whether
280 tocilizumab could sustain remission and enable glucocorticoid tapering.^{126, 127} In the phase III
281 RCT, sustained glucocorticoid-free remission at 52 weeks was achieved in more patients
282 treated with tocilizumab weekly (56%) or every other week (53%) (in combination with a
283 prednisone taper over 26 weeks) than in patients who received placebo plus a prednisone
284 taper over 26 weeks (14%) or placebo plus a prednisone taper over 52 weeks (18%).¹²⁷
285 Consequently, tocilizumab was approved for the treatment of patients with GCA by the FDA
286 and EMA in 2017, making this the first drug approved for the treatment of GCA other than
287 glucocorticoids. A phase III trial evaluating the efficacy and safety of sarilumab in patients
288 with GCA is currently ongoing.¹²⁸

289 In Takayasu arteritis, a double-blind RCT in Japan showed that, compared with placebo,
290 tocilizumab treatment prolonged the time to relapse during glucocorticoid tapering.¹²⁹
291 Although the primary end point of the study was not met, tocilizumab has been approved in
292 Japan for the treatment of Takayasu arteritis refractory to existing therapies.

293 Polymyalgia rheumatica (PMR) is a disease closely related to GCA, with stiffness and muscle
294 pain being the predominant symptoms. Several case reports and a small, prospective, open-
295 label phase II trial of tocilizumab in patients with PMR suggested that this drug might have a
296 steroid-sparing effect.^{130, 131} Another prospective open-label study found tocilizumab

297 monotherapy to be effective in new-onset PMR.¹³² Additional trials of IL-6 pathway
298 inhibition in PMR are ongoing, including phase III trials of tocilizumab and sarilumab.^{133,134}

299

300 **[H1] IL-6 inhibition in CRS**

301 Tocilizumab was approved by the FDA (in 2017) and EMA (in 2018) for the treatment of
302 severe or life threatening chimeric antigen receptor (CAR) T cell-induced cytokine release
303 syndrome (CRS) in adults and children. CAR T cells are ex vivo modified T cells from
304 patients with cancer, which are reprogrammed to lyse tumour cells when bound to a specific
305 cancer cell surface protein. However, ~70% of patients treated with a CD19 CAR T cell
306 therapy develop CRS.¹³⁵ CRS leads to headache, fever, chills, severe nausea, vomiting,
307 diarrhoea, musculoskeletal pain, dyspnea, hypotension and tachycardia, and in severe cases
308 can be fatal. The approval of tocilizumab for the treatment of CAR T cell-induced CRS was
309 based on retrospective analysis of data showing the efficacy of tocilizumab treatment in
310 patients who developed CRS after CAR T cell therapy in prospective clinical trials.¹³⁶⁻¹³⁸

311

312 **[H1] Other potential indications**

313 Unraveling the therapeutic potential of IL-6 pathway inhibition for indications other than
314 those discussed above is a matter of ongoing basic and clinical research spanning various
315 therapeutic areas.^{4,5} Several investigator-initiated studies are either planned or ongoing or
316 have already been published as proof-of-concept studies. A detailed representation of all of
317 these studies is beyond the scope of this article but briefly, they encompass conditions such as
318 uveitis, thyroid-eye disease, neuromyelitis optica, graft-versus-host disease, erosive hand
319 osteoarthritis, various oncological indications, depression, schizophrenia, Schnitzler

320 syndrome, myocardial infarction, familial Mediterranean fever, COVID-19 pneumonia
321 (caused by the novel coronavirus SARS-CoV-2) [Au:OK?Yes] and others.^{5, 139, 140} It is hoped
322 that findings from some of these studies will expand the application and medical value of IL-
323 6 pathway inhibition to additional diseases in the future.

324

325 [H1] Safety of IL-6 inhibition

326 The safety profile of IL-6R inhibition is derived mainly from clinical trials of tocilizumab
327 and sarilumab, as well as data from real-world registries of more than 1 million patients
328 worldwide who have been treated with tocilizumab, including patients with RA, JIA and
329 GCA.^{26, 53, 141-164}

330 Consistent with expectations for a biologic DMARD for RA, serious infections, including
331 bacterial serious infections, are among the most common serious adverse events reported in
332 clinical trials, post-marketing surveillance studies, short-term studies and open-label
333 extension studies. The overall rate of serious infections in patients with long-term exposure to
334 IL-6 pathway inhibitors is in line with rates seen in studies with a short duration of exposure.
335 ^{58, 142, 156, 158, 161-166}

336 Treatment with IL-6 pathway inhibitors has been associated with elevations in serum
337 concentrations of transaminases. These elevations did not seem to result in permanent or
338 clinically evident hepatic injury in clinical trials. An increased frequency and magnitude of
339 transaminase elevations was observed when potentially hepatotoxic drugs (for example,
340 methotrexate) were used in combination with IL-6 pathway inhibitors.¹⁶¹⁻¹⁶⁴

341 Pancreatitis is among the adverse reactions identified during post-approval use of tocilizumab
342 and sarilumab^{161, 163} Gastrointestinal perforations have also been associated with use of these
343 drugs; most such events occurred in patients with pre-existing risk factors (such as pre-

344 existing diverticulitis or use of oral glucocorticoids); thus, IL-6 pathway inhibitors should be
345 used with caution in patients with a history of gastrointestinal perforation, intestinal ulcers or
346 diverticulitis. The overall rate of gastrointestinal perforations in populations with long-term
347 exposure was in line with rates seen in short-duration studies.^{26, 161-164}

348 Monitoring of lipid profiles and treatment of hyperlipidemia according to clinical practice
349 guidelines is recommended during treatment with IL-6 inhibitors, as IL-6 pathway inhibition
350 is associated with increased serum lipid concentrations (LDL and triglycerides).^{151, 153}

351 Interestingly, IL-6 inhibition modifies HDL lipoproteins towards an anti-inflammatory
352 composition, thus the atherogenic index is unchanged [Au: edited sentence OK? Yes].¹⁶⁷⁻¹⁶⁹

353 In the ENTRACTE study, a head-to-head RCT comparing the cardiovascular safety of
354 tocilizumab and the TNF inhibitor etanercept in RA, the rate of major adverse cardiovascular
355 events was similar with both treatments (HR 1.05, 95% CI 0.77–1.43).¹⁷⁰

356 One safety concern of biologic therapies is the development of anti-drug antibodies, which
357 can lead to loss of efficacy and/or immune-mediated adverse reactions.¹⁷¹ A study evaluating
358 the immunogenicity of tocilizumab in patients with RA found that the incidence of anti-
359 tocilizumab antibodies was low [Au: Study description added, edit OK? Yes], regardless
360 of the route of administration of tocilizumab or whether it was used as monotherapy or in
361 combination with csDMARDs; moreover, anti-tocilizumab antibodies were mostly transient,
362 and their development did not correlate with pharmacokinetics, safety events or loss of
363 efficacy.¹⁷¹

364 For sirukumab, the FDA declined to approve the drug for use in RA owing to concern about
365 an imbalance in all-cause mortality between the sirukumab and placebo groups in phase III
366 studies, although whether this imbalance was a true safety signal or a result of the study

367 design is unclear.¹⁷² Additional studies are needed to further define the safety profile of
368 sirukumab.

369 In general, monitoring for adverse events should always follow local labels, which are
370 continuously updated with the latest safety information.¹⁶¹⁻¹⁶⁴

371

372 **[H1] Conclusions**

373 Substantial advances have been made in translating the biology of IL-6 to the treatment of
374 patients with autoimmune diseases. Accumulating safety data on IL-6 pathway inhibitors
375 have provided clinicians with the necessary knowledge for assessing the risk of using them.
376 IL-6 pathway inhibitors have shown benefit in patients with RA, JIA, AOSD, GCA,
377 Castleman's diseases and CRS, and might also be beneficial in patients with other
378 autoimmune diseases and even beyond. However, the limitations of preclinical studies for
379 predicting clinical success in patients is a major barrier and necessitates early human proof-
380 of-concept studies. Case reports or series have proved useful in some conditions such as
381 GCA, Takayasu arteritis, AOSD and CRS. In the future, trials to assess the efficacy and
382 safety of a specific treatment within a biomarker-positive subgroup in heterogeneous patient
383 populations (for example, a basket trial) to confirm and generate hypotheses might be an
384 option. However, a reliable biomarker for predicting treatment response in many rheumatic
385 diseases has not been identified.

386 Several questions relating to IL-6 biology remain unanswered. For example, why does IL-6
387 over-production occur and why does IL-6 signal inhibition lead to clinical meaningful
388 benefits for patients with some diseases associated with IL-6 over-production (such as RA)
389 but not all (such as AS)? Answering these questions would help to further progress our
390 understanding of how various autoimmune diseases are regulated in the context of IL-6

391 pathway biology and help in developing additional, personalized treatment options for
392 individual patients or patient subgroups. It seems that the journey of realizing the therapeutic
393 potential of IL-6 pathway inhibition is far from over.

394

395 **Acknowledgements**

396 The authors would like to acknowledge the support of B. Sudbeck in compiling clinical trial
397 information.

398

399 **Competing interests**

400 E.H.C. has received research grants from Bio-Cancer, Biogen, Novartis, Pfizer, Roche,
401 Sanofi and UCB, consultancy fees from Abbvie, Amgen, Biogen, Chugai Pharma, Eli Lilly,
402 Janssen, Novartis, Pfizer, Regeneron, Roche, R-Pharm and Sanofi, speaker's fees from
403 Amgen, Bristol Myer Squibbs, Chugai Pharma, Eli Lilly, Janssen, Novartis, Pfizer,
404 Regeneron, Roche, Sanofi, and UCB. F.D.B. has received research grants from AbbVie,
405 Novartis, Pfizer, Roche, Sanofi, Novimmune and SOBI. T.T. has received research grants
406 from AbbVie, Asahi Kasei Pharma Corp., Astellas Pharma, AYUMI Pharmaceutical
407 Corporation, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd.,
408 Mitsubishi Tanabe Pharma Co., Nipponkayaku Co. Ltd., Novartis Pharma K.K., Pfizer Japan,
409 Takeda Pharmaceutical Co., Ltd., and personal fees from Abbvie G.K., Astellas Pharma Inc,
410 Astra Zeneca K.K., Bristol-Myers K.K., Chugai Pharmaceutica Co., Ltd, Daiichi Sankyo Co,
411 Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical
412 K.K., Mitsubishi Tanabe Pharma Co., Nopponkayaku Co., Ltd, Novartis Pharma K.K., Pfizer
413 Japan Inc., Sanofi K.K., Teijin Pharma Ltd., Taiho Pharmaceutical Co. Ltd., Taisho
414 Pharmacetucial Co. Ltd., Takeda Pharmaceutical Co. Ltd., UCB Japan Co. Ltd.

415 M.H. is an employee of Chugai Pharmaceutical Co., Ltd. M.R.J. is employed by Roche and
416 owns shares in Roche. T.K. has a patent for tocilizumab. Work by T.K.'s group is supported
417 in part by the Kishimoto Foundation.

418

419 **References**

420

421 1. Kishimoto, T. & Ishizaka, K. Regulation of antibody response in vitro. VII.
422 Enhancing soluble factors for IgG and IgE antibody response. *J Immunol* **111**,
423 1194-205 (1973).

424 2. Hirano, T. et al. Complementary DNA for a novel human interleukin (BSF-2)
425 that induces B lymphocytes to produce immunoglobulin. *Nature* **324**, 73-76
426 (1986).

427 3. Hashizume, M. et al. Tocilizumab, a humanized anti-IL-6R antibody, as an
428 emerging therapeutic option for rheumatoid arthritis: molecular and cellular
429 mechanistic insights. *Int Rev Immunol* **34**, 265-279 (2015).

430 4. Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific
431 therapeutics for a complex cytokine. *Nat Rev Drug Discov* **17**, 395-412 (2018).

432 5. Kang, S., Tanaka, T., Narazaki, M. & Kishimoto, T. Targeting interleukin-6
433 signaling in clinic. *Immunity* **50**, 1007-1023 (2019).

434 6. Hibi, M. et al. Molecular cloning and expression of an IL-6 signal transducer,
435 gp130. *Cell* **63**, 1149-1157 (1990).

436 7. Yawata, H. et al. Structure-function analysis of human IL-6 receptor:
437 dissociation of amino acid residues required for IL-6-binding and for IL-6 signal
438 transduction through gp130. *EMBO J* **12**, 1705-12 (1993).

439 8. Waage, A., Kaufmann, C., Espevik, T. & Husby, G. Interleukin-6 in synovial fluid
440 from patients with arthritis. *Clin Immunol Immunopathol* **50**, 394-398 (1989).

441 9. Meyers, F.J. et al. Bladder cancer. Human leukocyte antigen II, interleukin-6,
442 and interleukin-6 receptor expression determined by the polymerase chain
443 reaction. *Cancer* **67**, 2087-2095 (1991).

444 10. Riechmann, L., Clark, M., Waldmann, H. & Winter, G. Reshaping human
445 antibodies for therapy. *Nature* **332**, 323-327 (1988).

446 11. Sato, K. et al. Reshaping a human antibody to inhibit the interleukin 6-
447 dependent tumor cell growth. *Cancer Res* **53**, 851-856 (1993).

448 12. Mihara, M. et al. Tocilizumab inhibits signal transduction mediated by both mIL-
449 6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
450 *Int Immunopharmacol* **5**, 1731-1740 (2005).

451 13. Kawano, M. et al. Autocrine generation and requirement of BSF-2/IL-6 for
452 human multiple myelomas. *Nature* **332**, 83-85 (1988).

453 14. Bataille, R. et al. Biologic effects of anti-interleukin-6 murine monoclonal
454 antibody in advanced multiple myeloma. *Blood* **86**, 685-691 (1995).

455 15. Lu, Z.Y. et al. Measurement of whole body interleukin-6 (IL-6) production:
456 prediction of the efficacy of anti-IL-6 treatments. *Blood* **86**, 3123-3231 (1995).

457 16. San-Miguel, J. et al. Phase 2 randomized study of bortezomib-melphalan-
458 prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. *Blood*
459 **123**, 4136-4142 (2014).

460 17. Yoshizaki, K. et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in
461 Castleman's disease. *Blood* **74**, 1360-1367 (1989).

462 18. Suematsu, S. et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. *Proc*
463 *Natl Acad Sci U S A* **86**, 7547-7551 (1989).

464 19. Katsume, A. et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses
465 Castleman's disease like symptoms emerged in IL-6 transgenic mice. *Cytokine*
466 **20**, 304-311 (2002).

467 20. Beck, J.T. et al. Brief report: alleviation of systemic manifestations of
468 Castleman's disease by monoclonal anti-interleukin-6 antibody. *N Engl J Med*
469 **330**, 602-605 (1994).

- 470 21. Nishimoto, N. et al. Improvement in Castleman's disease by humanized anti-
471 interleukin-6 receptor antibody therapy. *Blood* **95**, 56-61 (2000).
- 472 22. Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of
473 multicentric Castleman disease. *Blood* **106**, 2627-2632 (2005).
- 474 23. van Rhee, F. et al. Siltuximab for multicentric Castleman's disease: a
475 randomised, double-blind, placebo-controlled trial. *Lancet Oncol* **15**, 966-74
476 (2014).
- 477 24. Mitsuyama, K. et al. Soluble interleukin-6 receptors in inflammatory bowel
478 disease: relation to circulating interleukin-6. *Gut* **36**, 45-9 (1995).
- 479 25. Ito, H. et al. A pilot randomized trial of a human anti-interleukin-6 receptor
480 monoclonal antibody in active Crohn's disease. *Gastroenterology* **126**, 989-996
481 (2004).
- 482 26. Monemi, S. et al. Incidence of gastrointestinal perforations in patients with
483 rheumatoid arthritis treated with tocilizumab from clinical trial, postmarketing,
484 and real-world data sources. *Rheumatol Ther* **3**, 337-352 (2016).
- 485 27. Guerne, P.A., Zuraw, B.L., Vaughan, J.H., Carson, D.A. & Lotz, M. Synovium as
486 a source of interleukin 6 in vitro. Contribution to local and systemic
487 manifestations of arthritis. *J Clin Invest* **83**, 585-592 (1989).
- 488 28. Jilka, R.L. et al. Increased osteoclast development after estrogen loss: mediation
489 by interleukin-6. *Science* **257**, 88-91 (1992).
- 490 29. van de Loo, F.A., Joosten, L.A., van Lent, P.L., Arntz, O.J. & van den Berg, W.B.
491 Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage
492 proteoglycan metabolism and destruction. Effect of in situ blocking in murine
493 antigen- and zymosan-induced arthritis. *Arthritis Rheum* **38**, 164-172 (1995).
- 494 30. Poli, V. et al. Interleukin-6 deficient mice are protected from bone loss caused by
495 estrogen depletion. *EMBO J* **13**, 1189-96 (1994).
- 496 31. Takagi, N. et al. Blockage of interleukin-6 receptor ameliorates joint disease in
497 murine collagen-induced arthritis. *Arthritis Rheum* **41**, 2117-21 (1998).
- 498 32. Fujimoto, M. et al. Interleukin-6 blockade suppresses autoimmune arthritis in
499 mice by the inhibition of inflammatory T_H17 responses. *Arthritis Rheum* **58**,
500 3710-9 (2008).
- 501 33. Ohshima, S. et al. Interleukin 6 plays a key role in the development of antigen-
502 induced arthritis. *Proc. Natl Acad. Sci. USA* **95**, 8222-8226 (1998).
- 503 34. Wendling, D., Racadot, E. & Wijdenes, J. Treatment of severe rheumatoid
504 arthritis by anti-interleukin 6 monoclonal antibody. *J Rheumatol* **20**, 259-262
505 (1993).
- 506 35. Nishimoto, N., Kishimoto, T. & Yoshizaki, K. Anti-interleukin 6 receptor
507 antibody treatment in rheumatic disease. *Ann Rheum Dis* **59** (Suppl. 1), i21-i27
508 (2000).
- 509 36. Choy, E.H. et al. Therapeutic benefit of blocking interleukin-6 activity with an
510 anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a
511 randomized, double-blind, placebo-controlled, dose-escalation trial. *Arthritis*
512 *Rheum* **46**, 3143-3150 (2002).
- 513 37. Nishimoto, N. et al. Treatment of rheumatoid arthritis with humanized anti-
514 interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled
515 trial. *Arthritis Rheum* **50**, 1761-1769 (2004).
- 516 38. Maini, R.N. et al. Double-blind randomized controlled clinical trial of the
517 interleukin-6 receptor antagonist, tocilizumab, in European patients with
518 rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis*
519 *Rheum* **54**, 2817-2829 (2006).
- 520 39. Nishimoto, N. et al. Study of active controlled monotherapy used for rheumatoid
521 arthritis, an IL-6 inhibitor (SAMURAD): evidence of clinical and radiographic

- benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis* **66**, 1162-1167 (2007).
40. Jones, G. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis* **69**, 88-96 (2010).
41. Emery, P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* **67**, 1516-1523 (2008).
42. Genovese, M.C. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum* **58**, 2968-2980 (2008).
43. Smolen, J.S. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* **371**, 987-997 (2008).
44. Kremer, J.M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. *Arthritis Rheum* **63**, 609-621 (2011).
45. Takeuchi, T. et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study. *Rheumatology (Oxford)* **50**, 1908-1915 (2011).
46. Gabay, C. et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet* **381**, 1541-1550 (2013).
47. Dougados, M. et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis* **72**, 43-50 (2013).
48. Dougados, M. et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. *Ann Rheum Dis* **73**, 803-809 (2014).
49. Kaneko, Y. et al. Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study). *Ann Rheum Dis* **75**, 1917-1923 (2016).
50. Teitsma, X.M., Marijnissen, A.K., Bijlsma, J.W., Lafeber, F.P. & Jacobs, J.W. Tocilizumab as monotherapy or combination therapy for treating active rheumatoid arthritis: a meta-analysis of efficacy and safety reported in randomized controlled trials. *Arthritis Res Ther* **18**, 211 (2016).
51. Burmester, G.R. et al. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. *Ann Rheum Dis* **75**, 1081-1091 (2016).
52. Strand, V. et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. *RMD Open* **3**, e000496 (2017).
53. Jones, G. et al. Five-year efficacy and safety of tocilizumab monotherapy in patients with rheumatoid arthritis who were methotrexate- and biologic-naive or

- 573 free of methotrexate for 6 months: the AMBITION study. *J Rheumatol* **44**, 142-
574 146 (2017).
- 575 54. Burmester, G.R. et al. Tocilizumab combination therapy or monotherapy or
576 methotrexate monotherapy in methotrexate-naive patients with early
577 rheumatoid arthritis: 2-year clinical and radiographic results from the
578 randomised, placebo-controlled FUNCTION trial. *Ann Rheum Dis* **76**, 1279-1284
579 (2017).
- 580 55. Edwards, C.J., Ostor, A.J.K., Naisbett-Groet, B. & Kiely, P. Tapering versus
581 steady-state methotrexate in combination with tocilizumab for rheumatoid
582 arthritis: a randomized, double-blind trial. *Rheumatology* **57**, 84-91 (2018).
- 583 56. Kaneko, Y. et al. Tocilizumab discontinuation after attaining remission in
584 patients with rheumatoid arthritis who were treated with tocilizumab alone or in
585 combination with methotrexate: results from a prospective randomised controlled
586 study (the second year of the SURPRISE study). *Ann Rheum Dis* **77**, 1268-1275
587 (2018).
- 588 57. Kremer, J.M. et al. Sustained response following discontinuation of methotrexate
589 in patients with rheumatoid arthritis treated with subcutaneous tocilizumab:
590 results from a randomized, controlled trial. *Arthritis Rheumatol* **70**, 1200-1208
591 (2018).
- 592 58. Rubbert-Roth, A., Furst, D.E., Nebesky, J.M., Jin, A. & Berber, E. A review of
593 recent advances using tocilizumab in the treatment of rheumatic diseases.
594 *Rheumatol Ther* **5**, 21-42 (2018).
- 595 59. Teitsma, X.M. et al. Inadequate response to treat-to-target methotrexate therapy
596 in patients with new-onset rheumatoid arthritis: development and validation of
597 clinical predictors. *Ann Rheum Dis* **77**, 1261-1267 (2018).
- 598 60. Smolen, J.S. et al. EULAR recommendations for the management of rheumatoid
599 arthritis with synthetic and biological disease-modifying antirheumatic drugs:
600 2019 update. *Ann Rheum Dis* <https://doi.org/10.1136/annrheumdis-2019-216655>
601 (2020).
- 602 61. Dutch Association for Rheumatology. NVR Standpunt Tocilizumab verklaring
603 commissie kwaliteit Nov 2009. [https://www.nvr.nl/wp-](https://www.nvr.nl/wp-content/uploads/2018/09/NVR-Standpunt-Tocilizumab-verklaring-commissie-kwaliteit-nov-2009.pdf)
604 [content/uploads/2018/09/NVR-Standpunt-Tocilizumab-verklaring-commissie-](https://www.nvr.nl/wp-content/uploads/2018/09/NVR-Standpunt-Tocilizumab-verklaring-commissie-kwaliteit-nov-2009.pdf)
605 [kwaliteit-nov-2009.pdf](https://www.nvr.nl/wp-content/uploads/2018/09/NVR-Standpunt-Tocilizumab-verklaring-commissie-kwaliteit-nov-2009.pdf). (2009).
- 606 62. Schett, G. et al. FRI0050 Tocilizumab achieves better repair of focal bone erosions
607 than tumour necrosis factor inhibition in RA patients – data from the prospective
608 rebone study on erosion repair. *Ann Rheum Dis* **77**, 572-572 (2018).
- 609 63. Fonseca, J.E. et al. Portuguese guidelines for the use of biological agents in
610 rheumatoid arthritis - October 2011 update. *Acta Reumatol Port* **36**, 385-358
611 (2011).
- 612 64. Swedish Rheumatological Association. Guidelines for the pharmaceutical
613 management of rheumatoid arthritis. [http://svenskreumatologi.se/wp-](http://svenskreumatologi.se/wp-content/uploads/2016/08/guidelines_for_the_pharmaceutical_management_of_rheumatoid_arthritis.pdf)
614 [content/uploads/2016/08/guidelines_for_the_pharmaceutical_management_of_rhe-](http://svenskreumatologi.se/wp-content/uploads/2016/08/guidelines_for_the_pharmaceutical_management_of_rheumatoid_arthritis.pdf)
615 [umatoid_arthritis.pdf](http://svenskreumatologi.se/wp-content/uploads/2016/08/guidelines_for_the_pharmaceutical_management_of_rheumatoid_arthritis.pdf) (2011).
- 616 65. Gaujoux-Viala, C. et al. Recommendations of the French Society for
617 Rheumatology for managing rheumatoid arthritis. *Joint Bone Spine* **81**, 287-97
618 (2014).
- 619 66. Albrecht, K. et al. German guidelines for the sequential medical treatment of
620 rheumatoid arthritis with traditional and biologic disease-modifying
621 antirheumatic drugs. *Rheumatol Int* **34**, 1-9 (2014).
- 622 67. National Institute for Health and Care Excellence. Adalimumab, etanercept,
623 infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for

- 624 rheumatoid arthritis not previously treated with DMARDs or after conventional
625 DMARDs only have failed, <https://www.nice.org.uk/guidance/TA375>. (2016).
- 626 68. Smolen, J.S. et al. EULAR recommendations for the management of rheumatoid
627 arthritis with synthetic and biological disease-modifying antirheumatic drugs:
628 2016 update. *Ann Rheum Dis* **76**, 960-977 (2017).
- 629 69. Garcia-Vicuna, R. et al. Recommendations by the Spanish Society of
630 Rheumatology for the management of patients diagnosed with rheumatoid
631 arthritis who cannot be treated with methotrexate. *Reumatol Clin* **13**, 127-138
632 (2017).
- 633 70. Duarte, C. et al. Portuguese recommendations for the use of biological therapies
634 in patients with rheumatoid arthritis — 2016 update. *Acta Reumatol Port* **42(2)**,
635 112-126 (2017).
- 636 71. Moreland, L.W. & Curtis, J.R. Systemic nonarticular manifestations of
637 rheumatoid arthritis: focus on inflammatory mechanisms. *Semin Arthritis*
638 *Rheum* **39**, 132-143 (2009).
- 639 72. Davis, M.C. et al. Chronic stress and regulation of cellular markers of
640 inflammation in rheumatoid arthritis: implications for fatigue. *Brain Behav*
641 *Immun* **22**, 24-32 (2008).
- 642 73. Boyapati, A. et al. Sarilumab plus methotrexate suppresses circulating
643 biomarkers of bone resorption and synovial damage in patients with rheumatoid
644 arthritis and inadequate response to methotrexate: a biomarker study of
645 MOBILITY. *Arthritis Res Ther* **18**, 225 (2016).
- 646 74. Fleischmann, R. et al. Sarilumab and nonbiologic disease-modifying
647 antirheumatic drugs in patients with active rheumatoid arthritis and inadequate
648 response or intolerance to tumor necrosis factor inhibitors. *Arthritis Rheumatol*
649 **69**, 277-290 (2017).
- 650 75. Burmester, G.R. et al. Efficacy and safety of sarilumab monotherapy versus
651 adalimumab monotherapy for the treatment of patients with active rheumatoid
652 arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
653 *Ann Rheum Dis* **76**, 840-847 (2017).
- 654 76. Takeuchi, T. et al. Sirukumab for rheumatoid arthritis: the phase III
655 SIRROUND-D study. *Ann Rheum Dis* **76**, 2001-2008 (2017).
- 656 77. Aletaha, D. et al. Efficacy and safety of sirukumab in patients with active
657 rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a
658 randomised, double-blind, placebo-controlled, parallel-group, multinational,
659 phase 3 study. *Lancet* **389**, 1206-1217 (2017).
- 660 78. Taylor, P.C. et al. Efficacy and safety of monotherapy with sirukumab compared
661 with adalimumab monotherapy in biologic-naive patients with active rheumatoid
662 arthritis (SIRROUND-H): a randomised, double-blind, parallel-group,
663 multinational, 52-week, phase 3 study. *Ann Rheum Dis* **77**, 658-666 (2018).
- 664 79. Genovese, M.C. et al. Efficacy and safety of olokizumab in patients with
665 rheumatoid arthritis with an inadequate response to TNF inhibitor therapy:
666 outcomes of a randomised Phase IIb study. *Ann Rheum Dis* **73**, 1607-15 (2014).
- 667 80. Ravelli, A. & Martini, A. Juvenile idiopathic arthritis. *Lancet* **369**, 767-778
668 (2007).
- 669 81. De Benedetti, F. et al. Serum soluble interleukin 6 (IL-6) receptor and IL-
670 6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. *J Clin*
671 *Invest* **93**, 2114-2119 (1994).
- 672 82. Cazzola, M. et al. Defective iron supply for erythropoiesis and adequate
673 endogenous erythropoietin production in the anemia associated with systemic-
674 onset juvenile chronic arthritis. *Blood* **87**, 4824-4830 (1996).

- 675 83. De Benedetti, F. et al. Interleukin 6 causes growth impairment in transgenic
676 mice through a decrease in insulin-like growth factor-I. A model for stunted
677 growth in children with chronic inflammation. *J Clin Invest* **99**, 643-650 (1997).
- 678 84. De Benedetti, F. et al. Impaired skeletal development in interleukin-6-transgenic
679 mice: a model for the impact of chronic inflammation on the growing skeletal
680 system. *Arthritis Rheum* **54**, 3551-3563 (2006).
- 681 85. Hinze, C., Gohar, F. & Foell, D. Management of juvenile idiopathic arthritis:
682 hitting the target. *Nat Rev Rheumatol* **11**, 290-300 (2015).
- 683 86. Woo, P. et al. Open label phase II trial of single, ascending doses of MRA in
684 Caucasian children with severe systemic juvenile idiopathic arthritis: proof of
685 principle of the efficacy of IL-6 receptor blockade in this type of arthritis and
686 demonstration of prolonged clinical improvement. *Arthritis Res Ther* **7**, R1281-
687 R1288 (2005).
- 688 87. Yokota, S. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-
689 6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis.
690 *Arthritis Rheum* **52**, 818-825 (2005).
- 691 88. Yokota, S. et al. Efficacy and safety of tocilizumab in patients with systemic-
692 onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-
693 controlled, withdrawal phase III trial. *Lancet* **371**, 998-1006 (2008).
- 694 89. De Benedetti, F. et al. Randomized trial of tocilizumab in systemic juvenile
695 idiopathic arthritis. *N Engl J Med* **367**, 2385-2395 (2012).
- 696 90. Yokota, S. et al. Long-term treatment of systemic juvenile idiopathic arthritis
697 with tocilizumab: results of an open-label extension study in Japan. *Ann Rheum*
698 *Dis* **72**, 627-628 (2013).
- 699 91. Yokota, S. et al. Longterm safety and effectiveness of the anti-interleukin 6
700 receptor monoclonal antibody tocilizumab in patients with systemic juvenile
701 idiopathic arthritis in Japan. *J Rheumatol* **41**, 759-767 (2014).
- 702 92. De Benedetti, F. et al. Catch-up growth during tocilizumab therapy for systemic
703 juvenile idiopathic arthritis: results from a phase III trial. *Arthritis Rheumatol*
704 **67**, 840-848 (2015).
- 705 93. Yokota, S. et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-
706 world clinical setting: results from 1 year of postmarketing surveillance follow-up
707 of 417 patients in Japan. *Ann Rheum Dis* **75**, 1654-1660 (2016).
- 708 94. Kaneko, Y. et al. Tocilizumab in patients with adult-onset Still's disease
709 refractory to glucocorticoid treatment: a randomised, double-blind, placebo-
710 controlled phase III trial. *Ann Rheum Dis* **77**, 1720-1729 (2018).
- 711 95. Imagawa, T. et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor
712 monoclonal antibody, in patients with polyarticular-course juvenile idiopathic
713 arthritis. *Mod Rheumatol* **22**, 109-115 (2012).
- 714 96. Brunner, H.I. et al. Efficacy and safety of tocilizumab in patients with
715 polyarticular-course juvenile idiopathic arthritis: results from a phase 3,
716 randomised, double-blind withdrawal trial. *Ann Rheum Dis* **74**, 1110-1117 (2015).
- 717 97. Bharucha, K.N. et al. Growth during tocilizumab therapy for polyarticular-course
718 juvenile idiopathic arthritis: 2-year data from a phase III clinical trial. *J*
719 *Rheumatol* **45**, 1173-1179 (2018).
- 720 98. US National Library of Medicine. ClinicalTrials.gov.
721 <https://clinicaltrials.gov/ct2/show/NCT02776735>. (2020).
- 722 99. US National Library of Medicine. ClinicalTrials.gov.
723 <https://clinicaltrials.gov/ct2/show/NCT02991469> (2020).
- 724 100. Ambarus, C., Yeremenko, N., Tak, P.P. & Baeten, D. Pathogenesis of
725 spondyloarthritis: autoimmune or autoinflammatory? *Curr Opin Rheumatol* **24**,
726 351-8 (2012).

- 727 101. Ranganathan, V., Gracey, E., Brown, M.A., Inman, R.D. & Haroon, N.
728 Pathogenesis of ankylosing spondylitis — recent advances and future directions.
729 *Nat Rev Rheumatol* **13**, 359-367 (2017).
- 730 102. Gratacos, J. et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma)
731 in ankylosing spondylitis: a close correlation between serum IL-6 and disease
732 activity and severity. *Br J Rheumatol* **33**, 927-31 (1994).
- 733 103. Sieper, J., Porter-Brown, B., Thompson, L., Harari, O. & Dougados, M.
734 Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing
735 spondylitis: results of randomised, placebo-controlled trials. *Ann Rheum Dis* **73**,
736 95-100 (2014).
- 737 104. Sieper, J. et al. Sarilumab for the treatment of ankylosing spondylitis: results of
738 a Phase II, randomised, double-blind, placebo-controlled study (ALIGN). *Ann*
739 *Rheum Dis* **74**, 1051-1057 (2015).
- 740 105. Scher, J.U., Ogdie, A., Merola, J.F. & Ritchlin, C. Preventing psoriatic arthritis:
741 focusing on patients with psoriasis at increased risk of transition. *Nat Rev*
742 *Rheumatol* **15**, 153-166 (2019).
- 743 106. Partsch, G. et al. Highly increased levels of tumor necrosis factor-alpha and other
744 proinflammatory cytokines in psoriatic arthritis synovial fluid. *J Rheumatol* **24**,
745 518-523 (1997).
- 746 107. van Kuijk, A.W., Reinders-Blankert, P., Smeets, T.J., Dijkmans, B.A. & Tak, P.P.
747 Detailed analysis of the cell infiltrate and the expression of mediators of synovial
748 inflammation and joint destruction in the synovium of patients with psoriatic
749 arthritis: implications for treatment. *Ann Rheum Dis* **65**, 1551-1557 (2006).
- 750 108. Mease, P.J. et al. The efficacy and safety of clazakizumab, an anti-interleukin-6
751 monoclonal antibody, in a phase IIB study of adults with active psoriatic arthritis.
752 *Arthritis Rheumatol* **68**, 2163-2173 (2016).
- 753 109. Mihara, M. & Ohsugi, Y. Possible role of IL-6 in pathogenesis of immune
754 complex-mediated glomerulonephritis in NZB/W F1 mice: induction of IgG class
755 anti-DNA autoantibody production. *Int Arch Allergy Appl Immunol* **93**, 89-92
756 (1990).
- 757 110. Hirohata, S. & Miyamoto, T. Elevated levels of interleukin-6 in cerebrospinal
758 fluid from patients with systemic lupus erythematosus and central nervous
759 system involvement. *Arthritis Rheum* **33**, 644-649 (1990).
- 760 111. Gordon, C. et al. Urinary IL-6: a marker for mesangial proliferative
761 glomerulonephritis? *Clin Exp Immunol* **86**, 145-149 (1991).
- 762 112. Illei, G.G. et al. Tocilizumab in systemic lupus erythematosus: data on safety,
763 preliminary efficacy, and impact on circulating plasma cells from an open-label
764 phase I dosage-escalation study. *Arthritis Rheum* **62**, 542-552 (2010).
- 765 113. Shirota, Y. et al. Impact of anti-interleukin-6 receptor blockade on circulating T
766 and B cell subsets in patients with systemic lupus erythematosus. *Ann Rheum*
767 *Dis* **72**, 118-128 (2013).
- 768 114. Rovin, B.H. et al. A multicenter, randomized, double-blind, placebo-controlled
769 study to evaluate the efficacy and safety of treatment with sirukumab (CNTO
770 136) in patients with active lupus nephritis. *Arthritis Rheumatol* **68**, 2174-2183
771 (2016).
- 772 115. Wallace, D.J. et al. Efficacy and safety of an interleukin 6 monoclonal antibody
773 for the treatment of systemic lupus erythematosus: a phase II dose-ranging
774 randomised controlled trial. *Ann Rheum Dis* **76**, 534-542 (2017).
- 775 116. Kitaba, S. et al. Blockade of interleukin-6 receptor alleviates disease in mouse
776 model of scleroderma. *Am J Pathol* **180**, 165-176 (2012).

- 777 117. Kadono, T., Kikuchi, K., Ihn, H., Takehara, K. & Tamaki, K. Increased
778 production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. *J*
779 *Rheumatol* **25**, 296-301 (1998).
- 780 118. De Lauretis, A. et al. Serum interleukin 6 is predictive of early functional decline
781 and mortality in interstitial lung disease associated with systemic sclerosis. *J*
782 *Rheumatol* **40**, 435-446 (2013).
- 783 119. Shima, Y. et al. The skin of patients with systemic sclerosis softened during the
784 treatment with anti-IL-6 receptor antibody tocilizumab. *Rheumatology* **49**, 2408-
785 2412 (2010).
- 786 120. Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with
787 systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. *Lancet*
788 **387**, 2630-2640 (2016).
- 789 121. Khanna, D. et al. Efficacy and safety of tocilizumab for the treatment of systemic
790 sclerosis: results from a phase 3 randomized controlled trial. *Arthritis*
791 *Rheumatol.* **70 (Suppl. 10)**, 898 (2018).
- 792 122. Dejaco, C. et al. Giant cell arteritis and polymyalgia rheumatica: current
793 challenges and opportunities. *Nat Rev Rheumatol* **13**, 578-592 (2017).
- 794 123. Kim, E.S.H. & Beckman, J. Takayasu arteritis: challenges in diagnosis and
795 management. *Heart* **104**, 558-565 (2018).
- 796 124. Dasgupta, B. & Panayi, G.S. Interleukin-6 in serum of patients with polymyalgia
797 rheumatica and giant cell arteritis. *Br J Rheumatol* **29**, 456-458 (1990).
- 798 125. Noris, M., Daina, E., Gamba, S., Bonazzola, S. & Remuzzi, G. Interleukin-6 and
799 RANTES in Takayasu arteritis: a guide for therapeutic decisions? *Circulation*
800 **100**, 55-60 (1999).
- 801 126. Villiger, P.M. et al. Tocilizumab for induction and maintenance of remission in
802 giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
803 *Lancet* **387**, 1921-1927 (2016).
- 804 127. Stone, J.H. et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med* **377**,
805 317-328 (2017).
- 806 128. US National Library of Medicine. ClinicalTrials.gov.
807 <https://clinicaltrials.gov/ct2/show/NCT03600805> (2020).
- 808 129. Nakaoka, Y. et al. Efficacy and safety of tocilizumab in patients with refractory
809 Takayasu arteritis: results from a randomised, double-blind, placebo-controlled,
810 phase 3 trial in Japan (the TAKT study). *Ann Rheum Dis* **77**, 348-354 (2018).
- 811 130. Macchioni, P. et al. Tocilizumab for polymyalgia rheumatica: report of two cases
812 and review of the literature. *Semin Arthritis Rheum* **43**, 113-118 (2013).
- 813 131. Lally, L., Forbess, L., Hatzis, C. & Spiera, R. Brief report: a prospective open-
814 label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica.
815 *Arthritis Rheumatol* **68**, 2550-2554 (2016).
- 816 132. Devauchelle-Pensec, V. et al. Efficacy of first-line tocilizumab therapy in early
817 polymyalgia rheumatica: a prospective longitudinal study. *Ann Rheum Dis* **75**,
818 1506-1510 (2016).
- 819 133. US National Library of Medicine. ClinicalTrials.gov.
820 <https://clinicaltrials.gov/ct2/show/NCT03263715> (2020).
- 821 134. US National Library of Medicine. ClinicalTrials.gov.
822 <https://clinicaltrials.gov/ct2/show/NCT03600818> (2020).
- 823 135. Hay, K.A. Cytokine release syndrome and neurotoxicity after CD19 chimeric
824 antigen receptor-modified (CAR-) T cell therapy. *Br J Haematol* **183**, 364-374
825 (2018).
- 826 136. Grupp, S.A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid
827 leukemia. *N Engl J Med* **368**, 1509-1518 (2013).

- 828 137. Neelapu, S.S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory
829 large B-cell lymphoma. *N Engl J Med* **377**, 2531-2544 (2017).
- 830 138. Le, R.Q. et al. FDA approval summary: tocilizumab for treatment of chimeric
831 antigen receptor T cell-induced severe or life-threatening cytokine release
832 syndrome. *The Oncologist* **23**, 943-947 (2018).
- 833 139. Mehta, P. et al. COVID-19: consider cytokine storm syndromes and
834 immunosuppression. *Lancet* [https://doi.org/10.1016/S0140-6736\(20\)30628-0](https://doi.org/10.1016/S0140-6736(20)30628-0)
835 (2020).
- 836 140. Chinese Clinical Trial Registry. Chicttr.org.cn.
837 <http://www.chicttr.org.cn/showprojien.aspx?proj=49409>. (2020).
- 838 141. Koike, T. et al. Postmarketing surveillance of tocilizumab for rheumatoid
839 arthritis in Japan: interim analysis of 3881 patients. *Ann Rheum Dis* **70**, 2148-
840 2151 (2011).
- 841 142. Genovese, M.C. et al. Longterm safety and efficacy of tocilizumab in patients
842 with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. *J*
843 *Rheumatol* **40**, 768-780 (2013).
- 844 143. Koike, T. et al. Effectiveness and safety of tocilizumab: postmarketing
845 surveillance of 7901 patients with rheumatoid arthritis in Japan. *J Rheumatol*
846 **41**, 15-23 (2014).
- 847 144. Yamamoto, K. et al. Longterm safety of tocilizumab: results from 3 years of
848 followup postmarketing surveillance of 5573 patients with rheumatoid arthritis
849 in Japan. *J Rheumatol* **42**, 1368-1375 (2015).
- 850 145. Burmester, G.R. et al. Efficacy and safety of subcutaneous tocilizumab versus
851 intravenous tocilizumab in combination with traditional DMARDs in patients
852 with RA at week 97 (SUMMACTA). *Ann Rheum Dis* **75**, 68-74 (2016).
- 853 146. Kremer, J.M. et al. Clinical efficacy and safety maintained up to 5 years in
854 patients with rheumatoid arthritis treated with tocilizumab in a randomised
855 trial. *Clin Exp Rheumatol* **34**, 625-633 (2016).
- 856 147. Flaig, T. et al. Tocilizumab-induced pancreatitis: case report and review of data
857 from the FDA Adverse Event Reporting System. *J Clin Pharm Ther* **41**, 718-721
858 (2016).
- 859 148. Hoeltzenbein, M. et al. Tocilizumab use in pregnancy: analysis of a global safety
860 database including data from clinical trials and post-marketing data. *Semin*
861 *Arthritis Rheum* **46**, 238-245 (2016).
- 862 149. Kivitz, A. et al. Long-term safety and efficacy of subcutaneously administered
863 tocilizumab for adult rheumatoid arthritis: a multicenter phase 3b long-term
864 extension study. *Rheumatol Ther* **3**, 291-304 (2016).
- 865 150. Genovese, M.C. et al. Transaminase levels and hepatic events during tocilizumab
866 treatment: pooled analysis of long-term clinical trial safety data in rheumatoid
867 arthritis. *Arthritis Rheumatol* **69**, 1751-1761 (2017).
- 868 151. Kim, S.C. et al. Cardiovascular safety of tocilizumab versus tumor necrosis factor
869 inhibitors in patients with rheumatoid arthritis: a multi-database cohort study.
870 *Arthritis Rheumatol* **69**, 1154-1164 (2017).
- 871 152. Papalopoulos, I. et al. Liver safety of non-tumour necrosis factor inhibitors in
872 rheumatic patients with past hepatitis B virus infection: an observational,
873 controlled, long-term study. *Clin Exp Rheumatol* **36**, 102-109 (2018).
- 874 153. Kim, S.C. et al. No difference in cardiovascular risk of tocilizumab versus
875 abatacept for rheumatoid arthritis: a multi-database cohort study. *Semin*
876 *Arthritis Rheum* **48**, 399-405 (2018).
- 877 154. Rutherford, A.I., Subesinghe, S., Hyrich, K.L. & Galloway, J.B. Serious infection
878 across biologic-treated patients with rheumatoid arthritis: results from the

- 879 British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
880 *Ann Rheum Dis* **77**, 905-910 (2018).
- 881 155. Gron, K.L. et al. Risk of serious infections in patients with rheumatoid arthritis
882 treated in routine care with abatacept, rituximab and tocilizumab in Denmark
883 and Sweden. *Ann Rheum Dis* **78**, 320-327 (2019).
- 884 156. Curtis, J.R. et al. Tocilizumab in rheumatoid arthritis: a case study of safety
885 evaluations of a large postmarketing data set from multiple data sources. *Semin*
886 *Arthritis Rheum* **44**, 381-388 (2015).
- 887 157. Sakai, R. et al. Head-to-head comparison of the safety of tocilizumab and tumor
888 necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical
889 practice: results from the registry of Japanese RA patients on biologics for long-
890 term safety (REAL) registry. *Arthritis Res Ther* **17**, 74 (2015).
- 891 158. Morel, J. et al. Risk factors of serious infections in patients with rheumatoid
892 arthritis treated with tocilizumab in the French Registry REGATE.
893 *Rheumatology* **56**, 1746-1754 (2017).
- 894 159. Choy, E. et al. Evaluation of the efficacy and safety of sarilumab combination
895 therapy in patients with rheumatoid arthritis with inadequate response to
896 conventional disease-modifying antirheumatic drugs or tumour necrosis factor
897 alpha inhibitors: systematic literature review and network meta-analyses. *RMD*
898 *Open* **5**, e000798 (2019).
- 899 160. Emery, P. et al. Safety and tolerability of subcutaneous sarilumab and
900 intravenous tocilizumab in patients with rheumatoid arthritis. *Rheumatology* **58**,
901 849-858 (2018).
- 902 161. Tocilizumab package insert in the US
903 https://www.gene.com/download/pdf/actemra_prescribing.pdf.
- 904 162. Tocilizumab summary of product characteristics in EU
905 [http://ec.europa.eu/health/documents/community-](http://ec.europa.eu/health/documents/community-register/2018/20181029142753/anx_142753_en.pdf)
906 [register/2018/20181029142753/anx_142753_en.pdf](http://ec.europa.eu/health/documents/community-register/2018/20181029142753/anx_142753_en.pdf).
- 907 163. Sarilumab package insert in the US
908 <http://products.sanofi.us/kevezara/kevezara.pdf>.
- 909 164. Salirumab summary of product characteristics in EU
910 [https://www.ema.europa.eu/en/documents/product-information/kevezara-epar-](https://www.ema.europa.eu/en/documents/product-information/kevezara-epar-product-information_en.pdf)
911 [product-information_en.pdf](https://www.ema.europa.eu/en/documents/product-information/kevezara-epar-product-information_en.pdf).
- 912 165. Pardeo, M. et al. Neutropenia during tocilizumab treatment is not associated
913 with infection risk in systemic or polyarticular-course juvenile idiopathic
914 arthritis. *J Rheumatol* **46**, 1117-1126 (2019).
- 915 166. Nishimoto, N. et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6
916 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid
917 arthritis (the STREAM study): evidence of safety and efficacy in a 5-year
918 extension study. *Ann Rheum Dis* **68**, 1580-1584 (2009).
- 919 167. McInnes, I.B. et al. Effect of interleukin-6 receptor blockade on surrogates of
920 vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-
921 controlled study. *Ann Rheum Dis* **74**, 694-702 (2015).
- 922 168. Gabay, C. et al. Comparison of lipid and lipid-associated cardiovascular risk
923 marker changes after treatment with tocilizumab or adalimumab in patients
924 with rheumatoid arthritis. *Ann Rheum Dis* **75**, 1806-1812 (2016).
- 925 169. Fioravanti, A. et al. Tocilizumab modulates serum levels of adiponectin and
926 chemerin in patients with rheumatoid arthritis: potential cardiovascular
927 protective role of IL-6 inhibition. *Clin Exp Rheumatol* **37**, 293-300 (2019).
- 928 170. Scott, L.J. Tocilizumab: a review in rheumatoid arthritis. *Drugs* **77**, 1865-1879
929 (2017).

- 930 171. Burmester, G.R. et al. Low immunogenicity of tocilizumab in patients with
931 rheumatoid arthritis. *Ann Rheum Dis* **76**, 1078-1085 (2017).
- 932 172. FDA Summary Minutes of the Arthritis Advisory Committee Meeting August 2,
933 2017 <https://www.fda.gov/media/107409/download>.
- 934 173. Tsunenari, T. et al. New xenograft model of multiple myeloma and efficacy of a
935 humanized antibody against human interleukin-6 receptor. *Blood* **90**, 2437-2444
936 (1997).
- 937 174. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. Serum levels of interleukin 6, a
938 potent myeloma cell growth factor, as a reflect of disease severity in plasma cell
939 dyscrasias. *J Clin Invest* **84**, 2008-2011 (1989).
- 940 175. Atreya, R. et al. Blockade of interleukin 6 *trans* signaling suppresses T-cell
941 resistance against apoptosis in chronic intestinal inflammation: evidence in
942 crohn disease and experimental colitis in vivo. *Nat Med* **6**, 583-588 (2000).
- 943 176. Hosokawa, T. et al. Interleukin-6 and soluble interleukin-6 receptor in the colonic
944 mucosa of inflammatory bowel disease. *J Gastroenterol Hepatol* **14**, 987-996
945 (1999).
- 946 177. Pignatti, P. et al. Abnormal regulation of interleukin 6 in systemic juvenile
947 idiopathic arthritis. *J Rheumatol* **28**, 1670-1676 (2001).
- 948 178. De Benedetti, F. et al. Correlation of serum interleukin-6 levels with joint
949 involvement and thrombocytosis in systemic juvenile rheumatoid arthritis.
950 *Arthritis Rheum* **34**, 1158-1163 (1991).
- 951 179. Opoka-Winiarska, V. et al. Long-term, interventional, open-label extension study
952 evaluating the safety of tocilizumab treatment in patients with polyarticular-
953 course juvenile idiopathic arthritis from Poland and Russia who completed the
954 global, international CHERISH trial. *Clin. Rheumatol.* **37**, 1807-1816 (2018).
- 955 180. Hoshino, T. et al. Elevated serum interleukin 6, interferon-gamma, and tumor
956 necrosis factor-alpha levels in patients with adult Still's disease. *J Rheumatol* **25**,
957 396-398 (1998).
- 958 181. Tanaka, Y. et al. Production of B cell-stimulating factors by B cells in patients
959 with systemic lupus erythematosus. *J Immunol* **141**, 3043-309 (1988).
- 960 182. Gurrarn, M., Pahwa, S. & Frieri, M. Augmented interleukin-6 secretion in
961 collagen-stimulated peripheral blood mononuclear cells from patients with
962 systemic sclerosis. *Ann Allergy* **73**, 493-496 (1994).

963

964

965
966
967
968

Table 1. Evidence for the effects of IL-6 inhibition on diseases.

Disease	Cell based assays	Animal models	Biomarkers	Clinical trials	Drug(s) indicated
Multiple myeloma	IL-6 promotes myeloma cell proliferation ¹³	In the KPMM2 xenograft model, growth is IL-6-dependent ¹⁷³	Serum concentrations of IL-6 correlate with disease severity in plasma cell leukemia ¹⁷⁴	No improvement in clinical outcomes ^{14, 16}	None
Crohn's disease	IL-6 activates mucosal T cells ¹⁷⁵	IL-6R blockade promotes T cell apoptosis, which contributes chronic intestinal inflammation in the CD4 adoptive transfer colitis model ¹⁷⁵	Serum concentrations of sIL-6R are increased in active disease ²⁴ Concentrations of IL-6 and sIL-6R are increased in colonic organ cultures using specimens from patients with active disease ¹⁷⁶	Tocilizumab had a clinical effect in a pilot study ²⁵	None
Castleman's disease	IL-6 is produced by affected germinal centres ¹⁷	<i>IL6</i> transgenic mice develop clinical features of	Increased serum concentrations of IL-6 in active disease ¹⁷	Tocilizumab and siltuximab showed efficacy in	Tocilizumab Siltuximab

		Castleman's disease ¹⁹		clinical studies ^{22,23}	
RA	IL-6 involved in osteoporosis, cartilage destruction and synovial inflammation associated with RA ²⁷⁻²⁹	IL-6 inhibition prevented development of arthritis in CIA ^{31,32} and AIA ³³	Serum concentrations of IL-6 elevated in active RA	IL-6 pathway inhibition effective in many clinical trials ^{36-52, 54-57, 62}	Tocilizumab Sarilumab
Systemic JIA	Increased production of IL-6 by PBMCs ¹⁷⁷	<i>IL6</i> transgenic mice develop a skeletal phenotype resembling abnormalities observed in children with chronic inflammatory diseases ⁸⁴	Serum concentrations of IL-6 increased in patients with JIA and correlate with disease activity ^{81, 178}	Tocilizumab improved disease activity and reversed growth retardation ^{86-91, 93, 95, 179}	Tocilizumab
Adult-onset Still's disease	NA	NA	Serum concentrations of IL-6 increased ¹⁸⁰	Tocilizumab showed some clinical benefit and steroid-	Tocilizumab

				sparing effects ⁹⁴	
Ankylosing spondylitis	NA	NA	Serum concentrations of IL-6 are increased and correlate with disease activity ¹⁰²	Tocilizumab and sarilumab failed to show therapeutic benefit in RCTs ^{103,104}	None
Psoriatic arthritis	NA	NA	Serum and synovial fluid concentrations of IL-6 increased ^{106,107}	Clazakizumab improved arthritis, enthesitis, and dactylitis but not skin disease ¹⁰⁸	None
SLE	Increased production of IL-6 by B cells ¹⁸¹	IL-6 implicated in autoimmune disease pathogenesis in NZB/W F1 mice ¹⁰⁹	IL-6 concentrations increased in cerebrospinal fluid ¹¹⁰	IL-6 pathway inhibition affected autoantibody-producing cells but no clinically meaningful benefit demonstrated ^{112, 113}	None
Systemic sclerosis	Increased production of IL-6 by PBMCs ¹⁸²	IL-6 blockade improved disease in the bleomycin	Production of IL-6 increased in dermal fibroblasts and serum concentrations of IL-6	Tocilizumab had a potentially clinically important effect on preservation of lung	None

		n mouse model ¹¹⁶	increased ^{117, 118}	function ^{120, 121}	
Giant cell arteritis	NA	NA	Serum concentrations of IL-6 increased in active disease ¹²⁴	Tocilizumab was superior to placebo with regard to sustained glucocorticoid-free remission ^{126, 127}	Tocilizumab
Takayasu arteritis	NA	NA	Serum concentrations of IL-6 increased in active disease ¹²⁵	Tocilizumab had some effect on time to relapse but primary end point not met ¹²⁹	Tocilizumab
CRS	NA	NA	Serum concentrations of IL-6 increased ¹³⁶	Tocilizumab used successfully to treat CRS occurring in trials of CAR-T cell therapy ^{136, 137}	Tocilizumab

969
970
971
972
973
974
975
976

977 AIA, antibody-induced arthritis; CIA: collagen induced arthritis; CRS, cytokine release
978 syndrome; JIA, juvenile idiopathic arthritis; NA, not available; PBMC, peripheral blood
979 mononuclear cell; RA, rheumatoid arthritis; sIL-6R, soluble IL-6 receptor; SLE, systemic
980 lupus erythematosus.

981

982 **Figure legend**

983 **Figure 1: Timeline of the discovery of IL-6 and IL-6-targeted therapies.**

984 The timeline shows progress in the field of IL-6 pathway inhibition following the initial
985 identification of a B cell stimulation factor in 1976, and the more definitive biochemical and
986 molecular studies done in the 1980s and 1990s, to clinical trials and approvals in various
987 diseases in 2000s and to the present day. AOSD: adult onset Still's disease; AS: ankylosing
988 spondylitis; CRS: cytokine release syndrome; GCA: giant cell arteritis; gp130, glycoprotein
989 130; IL-6R, IL-6 receptor; LVV, large vessel vasculitis; pJIA: polyarticular course juvenile
990 idiopathic arthritis, RA, rheumatoid arthritis; SSc: systemic sclerosis; sJIA: systemic juvenile
991 idiopathic arthritis; SLE: systemic lupus erythematosus; Takayasu arteritis.

992

993 **Figure 2: Cell signalling pathways and physiological role of IL-6 in diseases.**

994

995 **IL-6 participates in a broad spectrum of biological events, such as synovial inflammation,**
996 **immune responses, haematopoiesis and acute-phase reactions [Au: Is this sentence in the**
997 **right place?Yes] . (a) IL-6 binds to IL-6 receptor (IL-6R) and glycoprotein 130 (gp130) to**
998 **form a hexameric complex. Both membrane-bound IL-6R and soluble IL-6R (sIL-6R) can be**
999 **part of the hexameric complex, and are associated with the classical and trans signalling**
1000 **pathways, respectively. Intracellular signalling pathways involve the Janus kinase (JAK) and**
1001 **signal transducer and activator of transcription (STAT) pathway. Pharmacological inhibitors**
1002 **of IL-6 signalling prevents IL-6 from binding to IL-6R by targeting either the cytokine itself**
1003 **or the receptor.**

1004 **(b) In the context of disease, IL-6 can have both local inflammatory and systemic effects.**
1005 **Some of the manifestations of the diseases for which IL-6 inhibitors are approved could be**
1006 **explained by the effects of IL-6, on the basis of both preclinical and clinical data. IL-6 has**
1007 **been implicated in the pathogenesis of diseases including rheumatoid arthritis, systemic**
1008 **juvenile idiopathic arthritis (sJIA), Castleman's disease, giant cell arteritis, Takayasu arteritis**
1009 **and cytokine release syndrome, among others (c) [Au: If there will be a third part to this**
1010 **figure, please provide the details (i.e. sketch and legend) via email, thanks by email]**

1011 CRP, C-reactive protein; MMP, matrix metalloprotease; RANKL, receptor activator of NF-
1012 κB ligand; SAA, serum amyloid A; VEGF, vascular endothelial growth factor.

1013

1014